References
- Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:1500–7
- Gibbs RS. The relationship between infections and adverse pregnancy outcomes: an overview. Ann Periodontol 2001;6:153–63
- Goldenberg RL, Culhane JF, Johnson DC. Maternal infection and adverse fetal and neonatal outcomes. Clin Perinatol 2005;32:523–59
- Carter TC, Olney RS, Mitchell AA, et al; National Birth Defects Prevention Study. Maternal self-reported genital tract infections during pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2011;91:108–16
- Goldenberg RL, McClure EM, Saleem S, Reddy UM. Infection-related stillbirths. Lancet 2010;375:1482–90
- Sanz E, Gómez-López T, Martínez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001;95:127–31
- Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet 2011;283:7–18
- Lin KJ, Mitchell AA, Yau WP, et al. Safety of macrolides during pregnancy. Am J Obstet Gynecol 2013;208:221.e1–8
- Bar-Oz B, Weber-Schoendorfer C, Berlin M, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf 2012;35:589–98
- WHO Collaborating Centre for Drug Statistics Methodology. International language for drug utilization research. ATC/DDD. Available from: http://www.whocc.no/ [last accessed 10 June 2013]
- Ministero della salute. Agenzia Italiana del Farmaco (AIFA). Farmaci e gravidanza. La valutazione del rischio teratogeno basata su prove di efficacia. Roma: AIFA; 2005
- Petersen I, Gilbert R, Evans S, et al. Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. J Antimicrob Chemother 2010;65:2238–46
- Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 2008;65:653–60
- Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. Br J Clin Pharmacol 2012;74:1053–62
- Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 2006;15:327–37
- Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65:839–46
- Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34:719–27
- Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;56:323–8
- US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf [last accessed 12 June 2013]
- Age.Na.S. Assistenza alla gravidanza e al parto fisiologico. Linee guida nazionali di riferimento. Available from: http://www.agenas.it/agenas_pdf/gravid_parto_2.pdf [last accessed 12 June 2013]